MedTrace Logo

Assessing Symptomatic Clinical Episodes in Depression

NCT03595579 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 97

Last updated 2021-09-24

Study results available
· View outcomes & findings →

Summary

Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.

Conditions

Interventions

DRUG

AXS-05

AXS-05 taken twice daily for 6 weeks.

DRUG

Bupropion

Bupropion taken twice daily for 6 weeks.

Sponsors & Collaborators

  • Axsome Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-30
Primary Completion
2019-01-07
Completion
2019-01-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03595579 on ClinicalTrials.gov